Stocks
Agios Pharmaceuticals, Inc.AGIO
NASDAQHealthcareBiotechnology$27.85+0.94%
Price as of · delayed, not real-time
Focused on developing therapies for rare genetic diseases and cancer, this biopharmaceutical company has attracted investor attention for its work in cellular metabolism. Its lead drug targets pyruvate kinase deficiency, a rare blood disorder, while its oncology pipeline includes investigational treatments for solid tumors. The company's valuation reflects both its commercialized products and potential in precision medicine.
Market Cap: $1.6B52W Range: $22.24 – $46.00
Congressional Interest in Agios Pharmaceuticals, Inc. (AGIO)
3 members of Congress have disclosed 7 trades in Agios Pharmaceuticals, Inc. (AGIO), a Healthcare company. The buy/sell breakdown shows 6 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
7
Unique Politicians
3
Buys
6
Sells
1
Who in Congress Is Trading AGIO?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-03 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-12-11 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-04-17 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-01-29 | Gilbert Cisneros | buy | $1K – $15K |
| 2024-01-24 | Josh Gottheimer | buy | $1K – $15K |
| 2015-05-27 | Thomas MacArthur | sell | $1K – $15K |
| 2015-03-18 | Thomas MacArthur | buy | $1K – $15K |